As the global pandemic persists, Perfectus Biomed continues efficacy testing of disinfectants and healthcare products against Coronavirus.
The coronavirus pandemic has required the disinfectant and biocides industry to react quickly to the fast-changing situation and produce products that support infection control, in the home and healthcare settings.
Since the beginning of the pandemic, we have redirected our focus and expanded our knowledge of our virology capabilities. We fast tracked disinfectants and healthcare product enquiries for efficacy testing against coronavirus and worked on innovative solutions to support our clients’ projects.
Below are just some of the tests and methods we perform to support coronavirus claims:
- Minimum requirements: For claims against enveloped viruses, disinfectants must be validated against the EN 14476:2013+A2:2019 standard using vaccinia virus. A 4-Log reduction is required to pass this test for contact times less than two minutes for hand hygiene products and less than 5 minutes for surface disinfectant products. This test covers all enveloped viruses including coronaviruses.
- For disinfectant efficacy against enveloped viruses on a surface, tests must be performed against the EN 16777:2018 standard using vaccinia virus. A pass for this test will also allow claims against enveloped viruses including coronaviruses.
- EN 17272 Airborne room disinfection testing
- We also provide tests against human coronavirus 229E, a surrogate virus, that has been used for regulatory claims specifically against coronavirus.
Our UK laboratory is ISO 9001 and ISO 17025 certified, UKAS accredited and GLP compliant and we are proud to offer excellent regulatory compliance and quality.
Should you have any further questions surrounding our coronavirus testing capabilities or have a product you would like to talk to us about, please contact us at email@example.com or telephone +44 (0)1925 737 237.